Drug Trial Radar · NCT05238675
A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
322
Actual
Start
Apr 28, 2022
Primary completion
May 1, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day. Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff. The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Bronchiectasis
Interventions
BI 1291583Drug
BI 1291583
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first pulmonary exacerbation up to 48 weeks after first drug administrationTime frame: Up to week 48
Locations
112 sites in 23 countries. Site status is shown where the registry gives one.
Phoenix Medical Group
Peoria, Arizona
Newport Native MD, Inc
Newport Beach, California
University of California Davis
Sacramento, California
Central Florida Pulmonary Group
Altamonte Springs, Florida
Malcom Randall VA Medical Center
Gainesville, Florida
University of Florida College of Medicine
Jacksonville, Florida
University of Kansas Medical Center
Kansas City, Kansas
New York University Langone Medical Center
New York, New York
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York
Southeastern Research Center
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Medical University of South Carolina
Charleston, South Carolina
Institute for Translational Oncology Research
Greenville, South Carolina
Metroplex Pulmonary & Sleep Center
McKinney, Texas
Diagnostics Research Group
San Antonio, Texas
University of Texas Health Science Center at Tyler
Tyler, Texas
Macquarie University
North Ryde, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Lung Research Queensland
Chermside, Queensland, Australia
Mater Research Institute
South Brisbane, Queensland, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Trialswest
Spearwood, Western Australia, Australia
UNIV UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Medical Center "Zdrave-1"
Kozloduy, Bulgaria
Medica Center Hera - Montana Branch
Montana, Bulgaria
Medical Center ReSpiro Ltd
Razgrad, Bulgaria
SHATPFD "Dr. Dimitar Gramatikov"
Rousse, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
Jewish General Hospital
Montreal, Migration Data, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
IUCPQ (Laval University)
Québec, Quebec, Canada
Pulmonary Private Practice Kralupy
Kralupy nad Vltavou, Czechia
The First Pulmonary Private Practice
Prague, Czechia
Aalborg Sygehus Syd
Aalborg, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Copenhagen University Hospital, Rigshospitalet
København Ø, Denmark
Odense University Hospital
Odense, Denmark
Sjællands Universitetshospital
Roskilde, Denmark
Vejle University Hospital
Vejle, Denmark
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.